According to the most recent filing that Royal London Asset Management Ltd made with the Securities and Exchange Commission, the investment management firm decreased its shares of Teleflex Incorporated (NYSE: TFX) during the third quarter.
After selling 892 shares during the period, the company now holds 15,707 shares of the stock held by a medical technology company.
This is after the sale of shares during the period.
The most recent disclosure that Royal London Asset Management Ltd made with the Securities and Exchange Commission revealed that the value of the company’s holdings in Teleflex was $3,166,000.
This information was provided to the SEC.
Several institutional investors and hedge funds have altered their respective holdings of TFX since we last checked in on them.
During the second quarter, Price T. Rowe Associates INC (MD) increased the amount of Teleflex stock owned by 20.3%, bringing its total ownership to 100%.
Price T. Rowe Associates INC (MD) now has 8,335,146 shares of the medical technology company’s stock, worth a total of $2,049,196 following the purchase of an additional 1,407,946 shares during the period.
This brings the total number of shares owned by the company to 8,335,146.
During the second quarter of the fiscal year, Brown Advisory INC increased the amount of money it had invested in Teleflex by 487.3 percent.
Brown Advisory INC now has a total of 404,946 shares of the stock of the medical technology company after purchasing an additional 336,013 shares during the period in question.
The stock has a value of $99,556,000, and the company has a market capitalization of $99,556,000.
The value of Allspring Global Investments Holdings LLC’s investment in Teleflex rose by 181.1% throughout the third quarter of 2018.
Allspring Global Investments Holdings LLC now has 366,320 shares of the medical technology company’s stock, which are currently valued at $73,797,000 following the acquisition of an additional 236,024 shares during the most recent period.
During the first three months of the year, Eaton Vance Management made a 141.3% increase in the proportion of Teleflex stock that it owned.
At the moment, Eaton Vance Management is the owner of a total of 284,639 shares of the stock held by the medical technology company.
The value of these shares is $100,999,000.
This is the result of acquiring 166,682 additional shares during the above period.
And finally, during the year’s second quarter, Thrivent Financial for Lutherans added a combined 170.8 percent to the Teleflex stock it held in its portfolio.
Thrivent Financial for Lutherans now has 159,404 shares of the medical technology company’s stock, which are now valued at $39,188,000 following the purchase of an additional 100,530 shares during the period in question.
Most of the company’s stock is owned by institutional investors and hedge funds, which account for 93.82% of the total.
When trading started on Thursday, the price of an individual share of TFX was $240.75.
According to the stock’s simple moving average over the past 200 days, the price is currently $230.51, and according to the stock’s simple moving average over the past 50 days, the price is currently $246.84.
The value of the quick ratio is 1.52, the current ratio is 2.39, and the value of the debt-to-equity ratio is 0.41.
All three ratios are in the same range.
During the previous year, the price of Teleflex Incorporated fluctuated between $182.65 and $356.72 at various points, reaching a low of $182.65 and a high of $356.72.
The company’s market capitalization is currently valued at $11.29 billion, and it possesses a price-to-earnings ratio of 27.61, a price-to-earnings-growth ratio of 2.72, and a beta coefficient of 0.99.
Recently, several market analysts have indicated that they are considering purchasing TFX stock.
Stephens increased their price target on Teleflex from $280.00 to $295.00 and categorized the stock as “overweight” in a research report published on Wednesday, December 28th. JMP Securities lowered its price objective for Teleflex from $370.00 to $330.00 and rated the company as “market outperform” in a report on the company that was published on Friday, October 28th.
The price target that Wells Fargo & Company has set for Teleflex has been reduced from $248.00 to $229.00, as stated in a research report that was made public on Friday, October 28th.
In addition, the company rated the stock as having “equal weight” in its portfolio.
In a research report made public on Friday, October 28th, the Royal Bank of Canada gave Teleflex a rating of “neutral,” which is a step down from the “outperform” rating it had previously given the company.
Additionally, the bank lowered its price objective for the company from $342.00 to $300.00, reflecting the current market conditions.
Last but not least, in a research note released on January 31st, Truist Financial lowered its “hold” rating and price objective on Teleflex, which had previously been set at $272.00.
These values are now set at $260.00.
Twelve research experts have evaluated the company, with six of them assigning it the rating of “hold” and the remaining twelve research experts evaluating the company assigning it the rating of “buy.” The current consensus rating for Teleflex is “Moderate Buy,” and the average price objective for the company is $268.58, according to the information provided by Bloomberg.
The medical technology that is produced by Teleflex, INC assists professionals working in the healthcare industry in their efforts to improve the outcomes for patients while simultaneously improving the safety of both the providers and the patients.
In critical care and surgical procedures, the company designs, develop, manufactures, and sells one-time-use medical equipment to hospitals and other healthcare facilities.
These products are used in critical care and surgical procedures.
Discussion about this post